STAT+: Roche drug sets new standard for KRAS-driven lung cancer 

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hi! As ever, lots going on in the light-speed world of biotech. The sector’s rally is gathering steam, the FDA’s AI flexibility is getting lost in translation, and Democrats lose a seasoned biopharma policymaker. 

But I’m still reeling from that synthetic biology SpudCell Matt Herper wrote about. 

Continue to STAT+ to read the full story…